Claims for Patent: 7,566,714

Summary for Patent: 7,566,714

Title:	Methods and compositions for the treatment of metabolic disorders
Abstract:	The present invention is directed to a novel methods and compositions for the therapeutic intervention in hyperphenylalaninemia. More specifically, the specification describes methods and compositions for treating various types of phenylketonurias using compositions comprising BH4. Combination therapies of BH4 and other therapeutic regimens are contemplated.
Inventor(s):	Oppenheimer; Daniel I. (Castro Valley, CA), Kakkis; Emil D. (Novato, CA), Price; Fredric D. (Bedford, NY), Dorenbaum; Alejandro (Mill Valley, CA), Moser; Rudolf (Schaffhausen, CH), Groehn; Viola (Dachsen, CH), Egger; Thomas (Kempthal, CH), Blatter; Fritz (Reinach, CH)
Assignee:	Biomarin Pharmaceutical Inc. (Novato, CA)
Application Number:	11/143,887
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,566,714
Patent Claims:	1. A method for treating a subject with hyperphenylalaninemia due to tetrahydrobiopterin-responsive phenylketonuria, comprising administering to said subject a therapeutically effective total daily dosage of tetrahydrobiopterin (BH4) or pharmaceutically acceptable salt thereof, wherein the administering is multiday, oral, and only once per day, and wherein the administering does not achieve controlled release of the BH4 in the gastrointestinal tract. 2. The method of claim 1, wherein the administering is for at least 7 days. 3. The method of claim 1, wherein the subject is administered BH4 for at least 2 weeks. 4. The method of claim 3, wherein said subject is administered BH4 for at least 6 weeks. 5. The method of claim 1, wherein said subject suffers from severe phenylketonuria, moderate phenylketonuria, or mild phenylketonuria. 6. The method of claim 5, wherein said subject suffers from severe phenylketonuria. 7. The method of claim 5, wherein said subject suffers from mild phenylketonuria. 8. The method of claim 5, wherein said subject has been diagnosed as having a mutant phenylalanine hydroxylase (PAH). 9. The method of claim 8, wherein said mutant PAH comprises a mutation in the catalytic domain of PAH. 10. The method of claim 8, wherein said mutation comprises one or more mutations selected from the group consisting of F39L, L48S, I65T, R68S, A104D, S110C, D129G, E178G, V190A, P211T, R241C, R261Q, A300S, L308F, A313T, K320N, A373T, V388M E390G, A395P, P407S, and Y414C. 11. The method of claim 5, wherein said subject has a plasma phenylalanine concentration of greater than 180 .mu.M prior to treatment with BH4. 12. The method of claim 5, wherein said subject has a plasma phenylalanine concentration of greater than 600 .mu.M prior to treatment with BH4. 13. The method of claim 5, wherein said subject has a plasma phenylalanine concentration of greater than 1000 .mu.M prior to treatment with BH4. 14. The method of claim 5, wherein said subject has a plasma phenylalanine concentration of greater than 1200 .mu.M prior to treatment with BH4. 15. The method of claim 5, wherein said administration of BH4 decreases the plasma phenylalanine concentration of said subject to less than 600 .mu.M. 16. The method of claim 5, wherein said administration of BH4 decreases the plasma phenylalanine concentration of said subject to less than 500 .mu.M. 17. The method of claim 5, wherein said administration of BH4 decreases the plasma phenylalanine concentration of said subject to less than 360 .mu.M. 18. The method of claim 5, wherein said BH4 is administered in a daily dose of between about 1 mg/kg to about 30 mg/kg. 19. The method of claim 5, wherein said BH4 is administered in a daily dose of between about 5 mg/kg to about 30 mg/kg. 20. The method of claim 5, wherein said BH4 is administered as a crystallized form stable for at least 3 months at 40.degree. C. and 75% relative humidity. 21. The method of claim 20, wherein said crystallized form of BH4 comprises at least 99.5% pure (6R)-5,6,7,8-tetrahydrobiopterin. 22. The method of claim 5, further comprising administering to said subject a protein-restricted diet. 23. The method of claim 22, wherein said protein-restricted diet is a phenylalanine-restricted diet wherein the total phenylalanine is restricted to less than 600 mg per day. 24. The method of claim 22, wherein said protein-restricted diet is a phenylalanine-restricted diet wherein the total phenylalanine is restricted to less than 300 mg per day. 25. The method of claim 22, wherein said subject is a pregnant female. 26. The method of claim 22, wherein said subject is an infant between the ages of 0 and 3 years of age. 27. The method of claim 22, wherein said subject is a female of child-bearing age that is contemplating pregnancy. 28. The method of claim 20, wherein said crystallized form of BH4 comprises purified polymorph B, wherein polymorph B, as a hydrochloride salt, exhibits an X-ray powder diffraction pattern with the following characteristic peaks expressed in d-values(A) 8.7 (vs), 5.63 (m), 4.76(m), 4.40 (m), 4.00 (s), 3.23 (s), 3.11 (vs), preferably 8.7 (vs), 6.9 (w), 5.90 (vw), 5.63 (m), 5.07 (m), 4.76 (m), 4.40 (m), 4.15 (w), 4.00 (s), 3.95 (m), 3.52 (m), 3.44 (w), 3.32 (m), 3.23 (s), 3.17 (w), 3.11 (vs), 3.06 (w), 2.99 (w), 2.96 (w), 2.94 (m), 2.87 (w), 2.84 (s), 2.82 (m), 2.69 (w), 2.59 (w), and 2.44 (w). 29. The method of claim 20, wherein said crystallized form of BH4 comprises purified polymorph A, wherein polymorph A, as a hydrochloride salt, exhibits an X-ray powder diffraction pattern with the following characteristic peaks expressed in d-values(A): 15.5 (vs), 12.0 (m), 6.7 (m), 6.5 (m), 6.3 (w), 6.1 (w), 5.96 (w), 5.49 (m), 4.89 (m), 3.79 (m), 3.70 (s), 3.48 (m), 3.45 (m), 3.33 (s), 3.26 (s), 3.22 (m), 3.18 (m), 3.08 (m), 3.02 (w), 2.95 (w), 2.87 (m), 2.79 (w), 2.70 (w). 30. The method of claim 20, wherein said crystallized form of BH4 comprises purified polymorph F, wherein polymorph F, as a hydrochloride salt, exhibits an X-ray powder diffraction pattern with the following characteristic peaks expressed in d-values(A): 17.1 (vs), 12.1 (w), 8.6 (w), 7.0 (w), 6.5 (w), 6.4 (w), 5.92 (w), 5.72 (w), 5.11 (w), 4.92 (m), 4.86 (w), 4.68 (m), 4.41 (w), 4.12 (w), 3.88 (w), 3.83 (w), 3.70 (m), 3.64 (w), 3.55 (m), 3.49 (s), 3.46 (vs), 3.39 (s), 3.33 (m), 3.31 (m), 3.27 (m), 3.21 (m), 3.19 (m), 3.09 (m), 3.02 (m), and 2.96 (m). 31. The method of claim 20, wherein said crystallized form of BH4 comprises purified polymorph J, wherein polymorph J, as a hydrochloride salt, exhibits an X-ray powder diffraction pattern with the following characteristic peaks expressed in d-values(A): 14.6 (m), 6.6 (w), 6.4 (w), 5.47 (w), 4.84 (w), 3.29 (vs), and 3.21 (vs). 32. The method of claim 20, wherein said crystallized form of BH4 comprises purified polymorph K, wherein polymorph K, as a hydrochloride salt, exhibits an X-ray powder diffraction pattern with the following characteristic peaks expressed in d-values(A): 14.0 (s), 9.4 (w), 6.6 (w), 6.4 (w), 6.3 (w), 6.1 (w), 6.0 (w), 5.66 (w), 5.33 (w), 5.13 (vw), 4.73 (m), 4.64 (m), 4.48 (w), 4.32 (vw), 4.22 (w), 4.08 (w), 3.88 (w), 3.79 (w), 3.54 (m), 3.49 (vs), 3.39 (m), 3.33 (vs), 3.13 (s), 3.10 (m), 3.05 (m), 3.01 (m), 2.99 (m), and 2.90 (m). 33. The method of claim 20, wherein said crystallized form of BH4 comprises purified hydrate C, wherein hydrate C, as a hydrochloride salt, exhibits an X-ray powder diffraction pattern with the following characteristic peaks expressed in d-values(A): 18.2 (m), 15.4 (w), 13.9 (vs), 10.4 (w), 9.6 (w), 9.1 (w), 8.8 (m), 8.2 (w), 8.0 (w), 6.8 (m), 6.5 (w), 6.05 (m), 5.77 (w), 5.64 (w), 5.44 (w), 5.19 (w), 4.89 (w), 4.76 (w), 4.70 (w), 4.41 (w), 4.25 (m), 4.00 (m), 3.88 (m), 3.80 (m), 3.59 (s), 3.50 (m), 3.44 (m), 3.37 (m), 3.26 (s), 3.19 (vs), 3.17 (s), 3.11 (m), 3.06 (m), 3.02 (m), 2.97 (vs), 2.93 (m), 2.89 (m), 2.83 (m), and 2.43 (m). 34. The method of claim 20, wherein said crystallized form of BH4 comprises purified hydrate D, wherein hydrate D, as a hydrochloride salt, exhibits an X-ray powder diffraction pattern with the following characteristic peaks expressed in d-values(A): 8.6 (s), 6.8 (w), 5.56 (m), 4.99 (m), 4.67 (s), 4.32 (m), 3.93 (vs), 3.88 (w), 3.64 (w), 3.41 (w), 3.25 (w), 3.17 (m), 3.05 (s), 2.94 (w), 2.92 (w), 2.88 (m), 2.85 (w), 2.80 (w), 2.79 (m), 2.68 (w), 2.65 (w), 2.52 (vw), 2.35 (w), 2.34 (w), 2.30 (w), and 2.29 (w). 35. The method of claim 20, wherein said crystallized form of BH4 comprises purified hydrate E, wherein hydrate E, as a hydrochloride salt, exhibits an X-ray powder diffraction pattern with the following characteristic peaks expressed in d-values(A): 15.4 (s), 6.6 (w), 6.5 (w), 5.95 (vw), 5.61 (vw), 5.48 (w), 5.24 (w), 4.87 (w), 4.50 (vw), 4.27 (w), 3.94 (w), 3.78 (w), 3.69 (m), 3.60 (w), 3.33 (s), 3.26 (vs), 3.16 (w), 3.08 (m), 2.98 (w), 2.95 (m), 2.91 (w), 2.87 (m), 2.79 (w), 2.74 (w), 2.69 (w), and 2.62 (w). 36. The method of claim 20, wherein said crystallized form of BH4 comprises purified hydrate H, wherein hydrate H, as a hydrochloride salt, exhibits an X-ray powder diffraction pattern with the following characteristic peaks expressed in d-values(A): 8.6 15.8 (vs), 10.3 (w), 8.0 (w), 6.6 (w), 6.07 (w), 4.81 (w), 4.30 (w), 3.87 (m), 3.60 (m), 3.27 (m), 3.21 (m), 3.13 (w), 3.05 (w), 2.96 (m), 2.89 (m), 2.82 (w), and 2.67 (m). 37. The method of claim 20, wherein said crystallized form of BH4 comprises purified hydrate O, wherein hydrate O, as a hydrochloride salt, exhibits an X-ray powder diffraction pattern with the following characteristic peaks expressed in d-values(A): 15.9 (w), 14.0 (w), 12.0 (w), 8.8 (m), 7.0 (w), 6.5 (w), 6.3 (m), 6.00 (w), 5.75 (w), 5.65 (m), 5.06 (m), 4.98 (m), 4.92 (m), 4.84 (w), 4.77 (w), 4.42 (w), 4.33 (w), 4.00 (m), 3.88 (m), 3.78 (w), 3.69 (s), 3.64 (s), 3.52 (vs), 3.49 (s), 3.46 (s), 3.42 (s), 3.32 (m), 3.27 (m), 3.23 (s), 3.18 (s), 3.15 (vs), 3.12 (m), 3.04 (vs), 2.95 (m), 2.81 (s), 2.72 (m), 2.67 (m), and 2.61 (m). 38. The method of claim 20, wherein said crystallized form of BH4 comprises purified solvate G, wherein solvate G, as a hydrochloride salt, exhibits an X-ray powder diffraction pattern with the following characteristic peaks expressed in d-values(A): 14.5 (vs), 10.9 (w), 9.8 (w), 7.0 (w), 6.3 (w), 5.74 (w), 5.24 (vw), 5.04 (vw), 4.79 (w), 4.41 (w), 4.02 (w), 3.86 (w), 3.77 (w), 3.69 (w), 3.63 (m), 3.57 (m), 3.49 (m), 3.41 (m), 3.26 (m), 3.17 (m), 3.07 (m), 2.97 (m), 2.95 (m), 2.87 (w), and 2.61 (w). 39. The method of claim 20, wherein said crystallized form of BH4 comprises purified solvate I, wherein solvate I, as a hydrochloride salt, exhibits an X-ray powder diffraction pattern with the following characteristic peaks expressed in d-values(A): 14.5 (m), 14.0 (w), 11.0 (w), 7.0 (vw), 6.9 (vw), 6.2 (vw), 5.30 (w), 4.79 (w), 4.44 (w), 4.29 (w), 4.20 (vw), 4.02 (w), 3.84 (w), 3.80 (w), 3.67 (vs), 3.61 (m), 3.56 (w), 3.44 (m), 3.27 (w), 3.19 (w), 3.11(s), 3.00 (m), 2.94 (w), 2.87 (w), and 2.80 (w). 40. The method of claim 20, wherein said crystallized form of BH4 comprises purified solvate L, wherein solvate L, as a hydrochloride salt, exhibits an X-ray powder diffraction pattern with the following characteristic peaks expressed in d-values(A): 14.1 (vs), 10.4 (w), 9.5 (w), 9.0 (vw), 6.9 (w), 6.5 (w), 6.1 (w), 5.75 (w), 5.61 (w), 5.08 (w), 4.71 (w), 3.86 (w), 3.78 (w), 3.46 (m), 3.36 (m), 3.06 (w), 2.90 (w), and 2.82 (w). 41. The method of claim 20, wherein said crystallized form of BH4 comprises purified solvate M, wherein solvate M, as a hydrochloride salt, exhibits an X-ray powder diffraction pattern with the following characteristic peaks expressed in d-values(A): 18.9 (s), 6.4 (m), 6.06 (w), 5.66 (w), 5.28 (w), 4.50 (w), 4.23 (w), and 3.22 (vs). 42. The method of claim 20, wherein said crystallized form of BH4 comprises purified solvate N, wherein solvate N, as a hydrochloride salt, exhibits an X-ray powder diffraction pattern with the following characteristic peaks expressed in d-values(A): 19.5 (m), 9.9 (w), 6.7 (w), 5.15 (w), 4.83(w), 3.91 (w), 3.56 (m), 3.33 (vs), 3.15 (w), 2.89 (w), 2.81 (w), 2.56 (w), and 2.36 (w). 43. The method of claim 1, wherein the BH4 is administered in a daily dose of about 10 mg/kg or more. 44. The method of claim 2, wherein the BH4 is administered in a daily dose of about 10 mg/kg or more. 45. The method of claim 3, wherein the BH4 is administered in a daily dose of about 10 mg/kg or more. 46. The method of claim 4, wherein the BH4 is administered in a daily dose of about 10 mg/kg or more.